Literature DB >> 16622027

Angiotensin II-induced mononuclear leukocyte interactions with arteriolar and venular endothelium are mediated by the release of different CC chemokines.

Teresa Mateo1, Yafa Naim Abu Nabah, May Abu Taha, Manuel Mata, Miguel Cerdá-Nicolás, Amanda E I Proudfoot, Rolf A K Stahl, Andrew C Issekutz, Julio Cortijo, Esteban J Morcillo, Peter J Jose, Maria-Jesus Sanz.   

Abstract

Angiotensin II (Ang-II) is associated with atherogenesis and arterial subendothelial mononuclear leukocyte infiltration. We have demonstrated that Ang-II causes the initial attachment of mononuclear cells to the arteriolar endothelium. We now report on the contribution of CC chemokines to this response. Intraperitoneal administration of 1 nM Ang-II induced MCP-1, RANTES, and MIP-1alpha generation, maximal at 4 h, followed by mononuclear leukocyte recruitment at 8 and 24 h. Using intravital microscopy within the rat mesenteric microcirculation 4 h after exposure to 1 nM Ang-II, arteriolar mononuclear cell adhesion was 80-90% inhibited by pretreatment with Met-RANTES, a CCR1 and CCR5 antagonist, or an anti-MCP-1 antiserum, without affecting the increased endothelial expression of P-selectin and VCAM-1. Conversely, leukocyte interactions with the venular endothelium, although inhibited by Met-RANTES, were little affected by the anti-MCP-1. Using rat whole blood in vitro, Ang-II (100 nM) induced the expression of monocyte CD11b that was inhibited by Met-RANTES but not by anti-MCP-1. Stimulation of human endothelial cells (human umbilical arterial endothelial cells and HUVECs) with 1-1000 nM Ang-II, predominantly acting at its AT(1) receptor, induced the release of MCP-1 within 1 h, RANTES within 4 h, and MCP-3 within 24 h. Eotaxin-3, a natural CCR2 antagonist, was released within 1 h and may delay mononuclear cell responses to MCP-1. Therefore, Ang-II-induced mononuclear leukocyte recruitment at arterioles and venules is mediated by the production of different CC chemokines. Thus, Ang-II may be a key molecule in the initial attachment of mononuclear cells to the arterial endothelium in cardiovascular disease states where this event is a characteristic feature.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16622027     DOI: 10.4049/jimmunol.176.9.5577

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  36 in total

1.  Mechanisms underlying the cerebral microvascular responses to angiotensin II-induced hypertension.

Authors:  Shantel A Vital; Satoshi Terao; Mutsumi Nagai; D Neil Granger
Journal:  Microcirculation       Date:  2010-11       Impact factor: 2.628

Review 2.  Monocytes as immune targets in arterial hypertension.

Authors:  Philip Wenzel
Journal:  Br J Pharmacol       Date:  2018-07-14       Impact factor: 8.739

3.  Combined treatment with bexarotene and rosuvastatin reduces angiotensin-II-induced abdominal aortic aneurysm in apoE(-/-) mice and angiogenesis.

Authors:  P Escudero; A Navarro; C Ferrando; E Furio; H Gonzalez-Navarro; M Juez; M J Sanz; L Piqueras
Journal:  Br J Pharmacol       Date:  2015-03-26       Impact factor: 8.739

Review 4.  COVID-19 as an Acute Inflammatory Disease.

Authors:  Rose H Manjili; Melika Zarei; Mehran Habibi; Masoud H Manjili
Journal:  J Immunol       Date:  2020-05-18       Impact factor: 5.422

Review 5.  Angiotensin-converting enzyme in innate and adaptive immunity.

Authors:  Kenneth E Bernstein; Zakir Khan; Jorge F Giani; Duo-Yao Cao; Ellen A Bernstein; Xiao Z Shen
Journal:  Nat Rev Nephrol       Date:  2018-03-26       Impact factor: 28.314

6.  C-C Motif Chemokine 5 Attenuates Angiotensin II-Dependent Kidney Injury by Limiting Renal Macrophage Infiltration.

Authors:  Nathan P Rudemiller; Mehul B Patel; Jian-Dong Zhang; Alexander D Jeffs; Norah S Karlovich; Robert Griffiths; Matthew J Kan; Anne F Buckley; Michael D Gunn; Steven D Crowley
Journal:  Am J Pathol       Date:  2016-09-15       Impact factor: 4.307

7.  Local angiotensin II aggravates cardiac remodeling in hypertension.

Authors:  Jiang Xu; Oscar A Carretero; Tang-Dong Liao; Hongmei Peng; Edward G Shesely; Junxiao Xu; Thomas S Liu; James J Yang; Timothy L Reudelhuber; Xiao-Ping Yang
Journal:  Am J Physiol Heart Circ Physiol       Date:  2010-09-10       Impact factor: 4.733

8.  Coronary risk assessment among intermediate risk patients using a clinical and biomarker based algorithm developed and validated in two population cohorts.

Authors:  D S Cross; C A McCarty; E Hytopoulos; M Beggs; N Nolan; D S Harrington; T Hastie; R Tibshirani; R P Tracy; B M Psaty; R McClelland; P S Tsao; T Quertermous
Journal:  Curr Med Res Opin       Date:  2012-11       Impact factor: 2.580

9.  Renin-angiotensin system activation correlates with microvascular dysfunction in a prospective cohort study of clinical sepsis.

Authors:  Kevin C Doerschug; Angela S Delsing; Gregory A Schmidt; Alix Ashare
Journal:  Crit Care       Date:  2010-02-22       Impact factor: 9.097

Review 10.  ACE2, angiotensin-(1-7) and Mas receptor axis in inflammation and fibrosis.

Authors:  A C Simões e Silva; K D Silveira; A J Ferreira; M M Teixeira
Journal:  Br J Pharmacol       Date:  2013-06       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.